JUST IN: Pfizer signs license agreement to allow broader global access to its experimental Covid-19 antiviral pill
The agreement with the Medicines Patent Pool, a United Nations-backed public health organization, would allow generic manufacturers to make the pill widely available in 95 low- and middle-income countries covering 53% of the world's population, the company said.The pill, known as PF-07321332 or Paxlovid, is to be given in combination with an older antiviral drug called ritonavir.
Molnupiravir is an oral Covid-19 antiviral for treatment of mild to moderate Covid-19 by adults who are at risk of severe Covid-19 and hospitalization. It was authorized by the UK Medicines and Healthcare Products Regulatory Agency earlier this month, and the companies have requested authorization from the US FDA.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Covid-19: Booster jabs for over-40s and Northern Ireland considers Covid passportsFive things you need to know about the coronavirus pandemic this Monday evening.
Les mer »
Pfizer agrees to let other companies make its COVID-19 pillLONDON (AP) — Drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill, a move that could make the treatment available to more than half of the world’s population.
Les mer »
COVID-19 surge fueled by unvaccinated children in U.K., a warning for CaliforniaThe U.K.'s challenges demonstrate how its overall vaccination efforts — while better than California's — are still not high enough for herd immunity.
Les mer »
Covid-19 Cases Rise in Pockets of North and West, Halting Delta Variant’s Decline in U.S.Covid-19 cases are climbing in the upper Midwest, Southwest and parts of the Northeast, stalling progress in ending the spread of the Delta variant just before Thanksgiving holiday travel.
Les mer »